Provided by Tiger Trade Technology Pte. Ltd.

Milliman Healthcare Inflation Plus ETF

20.49
-0.0324-0.16%
Post-market: 20.490.00000.00%16:10 EDT
Volume:11
Turnover:228
Market Cap:1.54M
PE:- -
High:20.49
Open:20.53
Low:20.49
Close:20.53
52wk High:22.57
52wk Low:19.45
Shares:75.00K
Float Shares:75.00K
Volume Ratio:0.83
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

All 50 States Sign up for Trump's Medicaid Most-Favored-Nation Plan

Reuters
·
Sep 18

When Weight Loss Isn't the Goal of Taking a GLP-1

Dow Jones
·
Sep 18

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 18

Goldman Sachs Adjusts Eli Lilly Price Target to $1,371 From $1,367, Maintains Buy Rating

MT Newswires Live
·
Sep 17